Buy IBRX by Jul 16, 2026.

**$IBRX DD: the class action headline looks scarier than the actual facts** Not financial advice. Just read the complaint, the FDA letter, the label, and the company response. **My take:** the lawsuit headline makes this sound like ImmunityBio’s core product got exposed as fake. That is **not** what happened. The class action is basically built around a **Jan. 19 podcast** and a TV ad, where Patrick Soon-Shiong made extremely aggressive claims about ANKTIVA — stuff like it could “treat all …